Prognostic Value of Microvascular Obstruction and Infarct Size, as Measured by CMR in STEMI Patients

6533b837fe1ef96bd12a1fef

RESEARCH PRODUCT

Prognostic Value of Microvascular Obstruction and Infarct Size, as Measured by CMR in STEMI Patients

Ronak Delewi Ingo Eitel Peter Bernhardt Bernhard Metzler Michael Magro Yves Cottin Matthijs Van Kranenburg Eric Boersma Edwin Wu Peter Buser Dan Atar Holger Thiele Vicente Bodi Felix Zijlstra Gert Klug Daniel C. Lee Wolfgang Rottbauer Robert-jan Van Geuns Suzanne De Waha Alexandre Cochet

subject

Male medicine.medical_specialty Time Factors medicine.medical_treatment microvascular obstruction Heart Ventricles Myocardial Infarction [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine Risk Assessment cardiac magnetic resonance [ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine Percutaneous Coronary Intervention Predictive Value of Tests Recurrence Risk Factors Internal medicine Coronary Circulation Medicine infarct size Humans Radiology Nuclear Medicine and imaging Myocardial infarction cardiovascular diseases Adverse effect ComputingMilieux_MISCELLANEOUS Aged Heart Failure business.industry Microcirculation Myocardium Hazard ratio Percutaneous coronary intervention Middle Aged medicine.disease Magnetic Resonance Imaging Confidence interval Treatment Outcome Radiology Nuclear Medicine and imaging Heart failure No reflow phenomenon Cardiology No-Reflow Phenomenon Female prognosis Cardiology and Cardiovascular Medicine business Mace

description

The aim of this study was to evaluate the value of microvascular obstruction (MO) and infarct size as a percentage of left ventricular mass (15%LV), as measured by contrast-enhanced cardiac magnetic resonance, in predicting major cardiovascular adverse events (MACE) at 2 years in patients with ST-segment elevation myocardial infarction reperfused by primary percutaneous coronary intervention. Individual data from 1,025 patients were entered into the pooled analysis. MO was associated with the occurrence of MACE, defined as a composite of cardiac death, congestive heart failure, and myocardial re-infarction (adjusted hazard ratio: 3.74; 95% confidence interval: 2.21 to 6.34). IS% LV >= 25% was not associated with MACE (adjusted hazard ratio: 0.90; 95% confidence interval: 0.59 to 1.37). The authors conclude that MO is an independent predictor of MACE and cardiac death, whereas IS%LV is not independently associated with MACE. (C) 2014 by the American College of Cardiology Foundation.

year	journal	country	edition	language
2014-09-01	JACC. Cardiovascular imaging

10.1016/j.jcmg.2014.05.010 https://doi.org/10.1016/j.jcmg.2014.05.010